sorafenib has been researched along with clopidogrel in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (clopidogrel) | Trials (clopidogrel) | Recent Studies (post-2010) (clopidogrel) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 10,221 | 1,918 | 5,951 |
| Protein | Taxonomy | sorafenib (IC50) | clopidogrel (IC50) |
|---|---|---|---|
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.562 | |
| P2Y purinoceptor 12 | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Tan-Shalaby, JL | 1 |
1 review(s) available for sorafenib and clopidogrel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and clopidogrel
| Article | Year |
|---|---|
Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Ticlopidine; Time Factors; Tomography, X-Ray Computed | 2014 |